February 27, 2006

New UK company focused on Schizophrenia

UK-headquartered Biofusion has announced the creation of Genophrenix, a new spin-out company from its pipeline agreement with the University of Sheffield. The unit has been formed to capitalize on the discovery of specific proteins that are involved with a key biochemical pathway implicated in a range of neuropsychiatric diseases, including schizophrenia. The initial discovery of these new proteins was the result of work carried out by Jamal Nasir, of the University of Sheffield Medical School. Biofusion owns 60% of the company.

Genophrenix believes that its discovery of proteins thought to play a role in the development of schizophrenia, will allow it to become an important partner to the pharmaceutical industry in developing new therapies and drug targets for the treatment of the condition. The company aims to develop packages of novel proprietary therapeutic targets and compounds which can be licensed to major global pharmaceutical companies focused on developing new treatments for schizophrenia.


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required